USPTO serial 79408203
LIGACHEM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 26, 2025
- Examiner
- SWAIN, MICHELE LYNN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with LIGACHEM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Richard Y. Kim
Richard Y. Kim Snell & Wilmer L.L.P.One East Washington Street, Suite 2700Phoenix, AZ 85004-2556United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Vaccines; food supplements; vitamin preparations; crude medicines for treating cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; nutraceuticals for use as a dietary supplement; biological preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical pharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; chemical preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical molecular diagnostic reagents for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; biopharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; syrups for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medicated lozenges for pharmaceutical purposes; capsules sold empty for pharmaceuticals; chemico-pharmaceutical preparations for pharmaceutical or medical purposes, namely, for cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; antibodies for medical purposes; medical antibodies, especially antibody conjugates and active ingredients and antibody conjugates; chemical reagents for medical use, especially chemical reagents for linking molecules for medical use; pharmaceutical compositions for use in treatment and prevention of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; plant extracts, other than essential oils, for medicinal purposes; pharmaceutical preparations for cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets; pharmaceutical preparations for the treatment and prevention of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; antibiotics; anti-cancer preparations; mixed vitamin preparations; chemotherapeutics; pharmaceutical preparations for the treatment of rare cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 16, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 2, 2026 | FINV | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 30, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 29, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 15, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 15, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 26, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 26, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 26, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 10, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 10, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 4, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 7, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 12, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 8, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 8, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 8, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 27, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 27, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 21, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 20, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 19, 2025 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Feb 19, 2025 | PBSR | WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST | — |
| Feb 14, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 12, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 12, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 12, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 8, 2024 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Oct 31, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |